Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx

BACKGROUND: CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) showed poor prognosis in the rituximab era, with limited research on its genetic characteristics and cell of origin (COO). We aimed to demonstrate the molecular characteristics of CD5+ DLBCL and to discover potential prognostic fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Dongshen, Ma, Yuhan, Ma, Yuanyuan, Liu, Jia, Gu, Ying, Liu, Nian, Xiang, Chenxi, Liu, Hui, Sang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445310/
https://www.ncbi.nlm.nih.gov/pubmed/36081566
http://dx.doi.org/10.3389/fonc.2022.941347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445310/
https://www.ncbi.nlm.nih.gov/pubmed/36081566
http://dx.doi.org/10.3389/fonc.2022.941347

Ejemplares similares